WntResearch AB

http://www.wntresearch.com/

Last activity: 09.10.2024

Probably Closed

Categories: BioTechBodyCauseDrugInformationMarketMobilityResearch

WntResearch is developing a completely new type of cancer drug that inhibits the ability of tumour cells to spread in the body and form metastases. The company's research is focused on studying the endogenous protein WNT5A, which in scientific studies has shown to affect tumour cells' ability to move and spread in the body. WntResearch drug candidate Foxy-5 is a peptide that mimics the function of WNT5A and is intended to reduce the mobility and spread of cancer cells thus preventing metastases from occurring. Although current cancer treatment has become more effective, there are no effective ways to prevent the onset of metastases that cause about 90 per cent of all cancerrelated deaths. Foxy-5 has a unique mechanism of action and has shown a good safety profile with few side effects in two Phase I clinical trials. The safety and efficacy of Foxy-5 are now being evaluated in the ongoing Phase 2 clinical trial NeoFox, in patients with stage II-III colon cancer. WntResearch is listed on the Spotlight Stock Market. For more information, please visit: www.wntresearch.com.

Followers

376

Website visits

10K /mo.

Mentions

Overview

Location

Sweden, Scania, Lund

Employees

11-50

Founded date

2007

Mentions in press and media 37

Reviews 0

FAQ about WntResearch AB

When was WntResearch AB founded?

WntResearch AB was founded in 2007.

What has the press written about WntResearch AB?

Parsers VC has collected 37 articles mentioning WntResearch AB, among them “BioStock: WntResearch plummets after results” (Sep 20, 2024) and “WntResearch presents ad hoc observations from the NeoFox study at ESMO GI” (Jun 20, 2024).

Is WntResearch AB still active?

WntResearch AB is probably closed: its latest activity on Parsers VC dates from Oct 9, 2024.

Date	Title	Description
Sign up to see	Sign up to see	Sign up to see
Sep 20, 2024	BioStock: WntResearch plummets after results	BioStock: WntResearch plummets after results Fri, Sep 20, 2024 09:15 CET Report this content The initial results from the NeoFox clinical phase II study have arrived. The safety seems to be good, but unfortunately, Foxy-5 appears to have li...
Jun 20, 2024	WntResearch presents ad hoc observations from the NeoFox study at ESMO GI	WntResearch presents ad hoc observations from the NeoFox study at ESMO GI Thu, Jun 20, 2024 20:01 CET Report this content WntResearch announces that a poster on the previously communicated positive ad hoc observations from the ongoing clini...
Feb 26, 2024	WntResearch initiates collaboration with Business Sweden with the goal of establishing commercial partnerships for Foxy-5 in Japan and South Korea	WntResearch initiates collaboration with Business Sweden with the goal of establishing commercial partnerships for Foxy-5 in Japan and South Korea Mon, Feb 26, 2024 08:00 CET Report this content WntResearch announces today that the company ...
Feb 12, 2024	WntResearch continues to the next step in the phase 2 study NeoFox with the highest evaluated dose of Foxy-5	WntResearch continues to the next step in the phase 2 study NeoFox with the highest evaluated dose of Foxy-5 Mon, Feb 12, 2024 08:00 CET Report this content WntResearch announces today that the company, after a very fast patient recruitment...
Feb 7, 2024	WntResearch carries out a directed issue of units to underwriters in connection with the completed rights issue	WntResearch carries out a directed issue of units to underwriters in connection with the completed rights issue Wed, Feb 07, 2024 19:30 CET Report this content Wntresearch AB (“WntResearch” or the “Company”) has completed the rights issue o...
Jan 31, 2024	WntResearch publishes outcome in rights issue	WntResearch publishes outcome in rights issue Wed, Jan 31, 2024 20:00 CET Report this content The board of directors of Wntresearch AB (“WntResearch” or the “Company”) today announces the outcome of the rights issue of units that was announ...
Jan 24, 2024	WntResearch's co-founder applies for subscription of additional units in the ongoing rights issue with a last day for subscription on 29 January 2024	WntResearch's co-founder applies for subscription of additional units in the ongoing rights issue with a last day for subscription on 29 January 2024 Wed, Jan 24, 2024 08:00 CET Report this content Tommy Andersson, co-founder and board memb...
Jan 8, 2024	WntResearch publishes prospectus in connection with rights issue	WntResearch publishes prospectus in connection with rights issue Mon, Jan 08, 2024 12:16 CET Report this content The board of directors of Wntresearch AB (“WntResearch” or the “Company”) has prepared an EU Growth Prospectus (the “Prospectus...
Dec 22, 2023	Bulletin from the extraordinary general meeting in Wntresearch AB on 22 December 2023	Bulletin from the extraordinary general meeting in Wntresearch AB on 22 December 2023 Fri, Dec 22, 2023 14:00 CET Report this content Today, on 22 December 2023, an extraordinary general meeting was held in Wntresearch AB. A summary of the ...
Dec 6, 2023	WntResearch continues to the second dose group in clinical proof of concept study of Foxy-5	WntResearch continues to the second dose group in clinical proof of concept study of Foxy-5 Wed, Dec 06, 2023 08:30 CET Report this content WntResearch today announces that the safety evaluation from the first cohort in the dose-finding par...
Nov 23, 2023	WntResearch's scientific founder publishes study on WNT5A signaling in scientific journal	WntResearch's scientific founder publishes study on WNT5A signaling in scientific journal Thu, Nov 23, 2023 15:18 CET Report this content WntResearch announces today that a study describing WNT5A signaling and its mechanism of action has be...
Nov 20, 2023	WntResearch carries out a rights issue of units of approximately SEK 56 million	WntResearch carries out a rights issue of units of approximately SEK 56 million Mon, Nov 20, 2023 23:49 CET Report this content The Board of Directors of Wntresearch AB ("WntResearch" or the “Company") has today, subject to s...
Oct 25, 2023	WntResearch and Collective Minds Radiology sign agreement for quality assurance of clinical study	WntResearch and Collective Minds Radiology sign agreement for quality assurance of clinical study Wed, Oct 25, 2023 13:30 CET Report this content WntResearch and Collective Minds Radiology announce that the companies have signed an agreemen...
Oct 18, 2023	WntResearch has included the first patient in the redesign of the proof of concept study NeoFox with the drug candidate Foxy-5	WntResearch has included the first patient in the redesign of the proof of concept study NeoFox with the drug candidate Foxy-5 Wed, Oct 18, 2023 15:13 CET Report this content WntResearch announced today that the first patient has been inclu...
Jul 10, 2023	Implementation of incentive programmes in Wntresearch AB	Implementation of incentive programmes in Wntresearch AB Mon, Jul 10, 2023 07:39 CET Report this content The two incentive programmes for Wntresearch AB ("WntResearch" or the "Company") that were resolved by the Extraord...
Jul 6, 2023	NeoFox revised study plan approved	NeoFox revised study plan approved Thu, Jul 06, 2023 21:00 CET Report this content The Spanish regulatory authorities have approved the revised study plan for the phase 2 NeoFox study for the drug candidate Foxy-5. Due to the reported unexp...
Jun 21, 2023	Potential role of WNT5A and Foxy-5 in AML published in Journal of Cell Communication and Signaling article	Potential role of WNT5A and Foxy-5 in AML published in Journal of Cell Communication and Signaling article Wed, Jun 21, 2023 13:15 CET Report this content An article has been published in the renowned scientific journal Journal of Cell Comm...
Jun 16, 2023	Joachim Gullbo, Scientific Advisor	Joachim Gullbo, Scientific Advisor Fri, Jun 16, 2023 10:16 CET Report this content WntResearch has once again engaged Joachim Gullbo as scientific advisor, a role he previously held but had to leave when he started a position in the United ...
May 29, 2023	Find your next investment at the BioStock Life Science Spring Summit on May 30 and 31!	Find your next investment at the BioStock Life Science Spring Summit on May 30 and 31! Mon, May 29, 2023 09:45 CET Report this content It is finally time for BioStock Life Science Spring Summit 2023! Around 30 companies from a wide range of...
Apr 25, 2023	CEO Pernilla Sandwall attends the Nordic Health Summit Japan	CEO Pernilla Sandwall attends the Nordic Health Summit Japan Tue, Apr 25, 2023 11:46 CET Report this content The conference will take place in Tokyo on April 25, 2023. Keynote speakers are representatives from both Eisai, Solasia, AstraZene...
Mar 27, 2023	CEO Pernilla Sandwall presents the company at Swiss Nordic Bio 30 March	CEO Pernilla Sandwall presents the company at Swiss Nordic Bio 30 March Mon, Mar 27, 2023 14:19 CET Report this content The conference will take place in Zurich on March 30, 2023. Pernilla will present the company and the drug candidate Fox...
Mar 17, 2023	WntResearch attends the BIO-Europe partnering conference in Basel March 20-22	WntResearch attends the BIO-Europe partnering conference in Basel March 20-22 Fri, Mar 17, 2023 12:11 CET Report this content BIO-Europe is a partnering conference in the life science industry that enables meetings with potential partners. ...
Mar 17, 2023	CEO Pernilla Sandwall invited to present Foxy-5 at scientific workshop on Wnt signalling in Heidelberg on 17 March	CEO Pernilla Sandwall invited to present Foxy-5 at scientific workshop on Wnt signalling in Heidelberg on 17 March Fri, Mar 17, 2023 11:56 CET Report this content Six researchers and two pharmaceutical company representatives active in Wnt ...
Jan 26, 2023	WntResearch announces the last day for trading in BTU and the first day for trading in warrants series TO 6	WntResearch announces the last day for trading in BTU and the first day for trading in warrants series TO 6 Thu, Jan 26, 2023 17:30 CET Report this content NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, TH...
Jan 25, 2023	WntResearch carries out a directed issue of units to underwriters in connection with the completed rights issue	WntResearch carries out a directed issue of units to underwriters in connection with the completed rights issue Wed, Jan 25, 2023 14:28 CET Report this content NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO...
Jan 17, 2023	WntResearch publishes outcome in rights issue and information on warrants series TO 5	WntResearch publishes outcome in rights issue and information on warrants series TO 5 Tue, Jan 17, 2023 16:42 CET Report this content The board of directors of Wntresearch AB (“WntResearch” or the “Company”) today announces the outcome of t...
Jan 9, 2023	The CEO applies for subscription of additional units in WntResearch’s ongoing rights issue with last day for subscription on 13 January 2023	The CEO applies for subscription of additional units in WntResearch’s ongoing rights issue with last day for subscription on 13 January 2023 Mon, Jan 09, 2023 08:00 CET Report this content NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIREC...
Dec 14, 2022	WntResearch publishes prospectus in connection with rights issue	WntResearch publishes prospectus in connection with rights issue Wed, Dec 14, 2022 16:35 CET Report this content The board of directors of Wntresearch AB (“WntResearch” or the “Company”) has prepared an EU Growth Prospectus (the “Prospectus...
Dec 12, 2022	Bulletin from the extraordinary general meeting in Wntresearch AB on 12 December 2022 as well as update on subscription period in rights issue of units	Bulletin from the extraordinary general meeting in Wntresearch AB on 12 December 2022 as well as update on subscription period in rights issue of units Mon, Dec 12, 2022 11:00 CET Report this content Today, on 12 December 2022, an extraordi...
Nov 15, 2022	Revised study plan for NeoFox Phase 2 clinical trial with Foxy-5, resulting in time and cost savings	Revised study plan for NeoFox Phase 2 clinical trial with Foxy-5, resulting in time and cost savings Tue, Nov 15, 2022 14:30 CET Report this content Following the reported observations of the unexpectedly positive effects of Foxy-5 in colon...
Nov 14, 2022	Clarification on the observations of the unexpected positive effects of Foxy-5 in colon cancer	Clarification on the observations of the unexpected positive effects of Foxy-5 in colon cancer Mon, Nov 14, 2022 13:31 CET Report this content As previously announced by the company, the ad hoc analysis has shown that Foxy-5 treated patient...
Aug 16, 2022	Interesting clinical observations lead to changed plans for WntResearch	Interesting clinical observations lead to changed plans for WntResearch Tue, Aug 16, 2022 08:15 CET Report this content In connection with an ongoing post hoc analysis of the NeoFox phase 2 study, a reduced tumour burden (in primary tumour ...
Mar 28, 2022	June 2 new date for WntResearch Annual General Meeting	June 2 new date for WntResearch Annual General Meeting Mon, Mar 28, 2022 13:00 CET Report this content The Board of Directors has decided to postpone the date of the Annual General Meeting to Thursday, June 2, taking into account that Perni...
Feb 13, 2022	WntResearch : appoints new CEO with effect from April	Press release from Companies Published: 2022-02-13 20:15:00 WntResearch AB: WntResearch appoints new CEO with effect from April The Board has appointed Pernilla Sandwall as the new CEO of WntResearch AB with effect from April 29. The curren...
Jan 17, 2022	WntResearch files a patent application expanding the commercial potential of Foxy-5	WntResearch files a patent application expanding the commercial potential of Foxy-5 Mon, Jan 17, 2022 09:37 CET WntResearch is broadening its potential patent protection according to the commercial strategy by filing an international patent...
Dec 13, 2021	WntResearch files a patent application for the treatment of Acute Myeloid Leukemia	WntResearch files a patent application for the treatment of Acute Myeloid Leukemia Mon, Dec 13, 2021 11:16 CET WntResearch announces today that the company has filed a new patent application that broadly covers the use of Foxy-5 in the trea...